Novartis Highlights its Blockbuster Portfolio at R&D Day 2019

 Novartis Highlights its Blockbuster Portfolio at R&D Day 2019

Novartis Highlights its Blockbuster Portfolio at R&D Day 2019

Shots:

  • Novartis reports that it has 60 projects in P-II with expected 10+ products to enter in P-III study in 2020 & 2021 while 90% of them are first-in-class or first-in-indication therapies. Novartis emphasizes its focus on innovative medicines, diversification across therapeutic areas and exposure to cutting-edge platforms
  • Novartis presents its emerging assets including Iscalimab in transplant & Sjögren’s syndrome, LNP023 in renal diseases & PNH, MBG453 in MDS, and TQJ230 in the reduction of CV risk. The company divulges its expected near-term launches including ofatumumab for relapsing MS, Fevipiprant for Asthma, Radioligand Therapy Lu-PSMA-617 for PC, Adakveo for SCD and Canakinumab in lung cancer
  • Novartis is exploring 40+ new indication to maximize the potential of in-line brands, including up to 7 for its Cosentyx and others for Beovu, Piqray and Kisqali and its NIBR team is examining 90+ NMEs including TNO155, being developed for advanced solid tumors with RASG12C mutations

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: GMP News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post